XML 52 R25.htm IDEA: XBRL DOCUMENT
v3.25.1

Consolidated Statements of Operations Information | 12 Months Ended
--- | ---
Dec. 31, 2024
Consolidated Statements of Operations Information |
Consolidated Statements of Operations Information | Note 17. Consolidated Statements of Operations Information Revenue The Group’s revenue comprised: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Years ended December 31: |  | 2024 |  | 2023 |  | 2022
Royalty, goods and products and services | ​ | $ | 24,279 | ​ | $ | 43,330 | ​ | $ | 52,218
Interest | ​ |  | 3,210 | ​ |  | 3,717 | ​ |  | 3,712
Dividends | ​ | ​ | 166 | ​ | ​ | 146 | ​ | ​ | 268
Other, including medical and real estate sectors | ​ | ​ | 7,647 | ​ | ​ | 7,751 | ​ | ​ | 7,491
Revenue | ​ | $ | 35,302 | ​ | $ | 54,944 | ​ | $ | 63,689
​ The revenue of $24,279 from royalty, goods and products and services for the year ended December 31, 2024 comprised royalty revenue of $20,046, energy of $4,171 and fees of $62. ​ The revenue of $43,330 from royalty, goods and products and services for the year ended December 31, 2023 comprised royalty revenue of $35,234, energy of $6,931 and fees of $1,165. The revenue of $52,218 from royalty, goods and products and services for the year ended December 31, 2022 comprised royalty revenue of $28,970, energy of $21,555 and fees of $1,693. Costs and Expenses The Group’s costs of sales and services comprised: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Years Ended December 31: |  | 2024 |  | 2023 |  | 2022
Royalty, goods and products and services | ​ | $ | 8,532 | ​ | $ | 12,689 | ​ | $ | 23,677
Write-down (Reversal of write-down) of inventories | ​ | ​ | 19 | ​ | ​ | (27) | ​ | ​ | (21)
Net fair value loss (gain) on investment property | ​ | ​ | (2,005) | ​ | ​ | 59 | ​ | ​ | (96)
Gain on dispositions of subsidiaries, net | ​ | ​ | (3,646) | ​ | ​ | — | ​ | ​ | (264)
Gains on settlements and derecognition of liabilities | ​ | ​ | — | ​ | ​ | (1,313) | ​ | ​ | (69)
Change in fair value of loan payable measured at FVTPL | ​ | ​ | (1,197) | ​ | ​ | 360 | ​ | ​ | 141
Losses on securities, net | ​ | ​ | 218 | ​ | ​ | 2,794 | ​ | ​ | 2,436
Other, including medical and real estate sectors | ​ | ​ | 5,142 | ​ | ​ | 4,512 | ​ | ​ | 4,078
Total costs of sales and services | ​ | $ | 7,063 | ​ | $ | 19,074 | ​ | $ | 29,882
​ ​ Note 17. Consolidated Statements of Operations Information (continued) The Group’s net gain from dispositions of subsidiaries comprised: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Years Ended December 31: |  | 2024 |  | 2023 |  | 2022
Net liabilities in excess of considerations received |  | $ | (3,646) |  | $ | — |  | $ | (273)
Reclassification adjustment for the exchange differences upon dispositions of subsidiary | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 9
Gain on disposition of subsidiary, net (see Note 27) |  | $ | (3,646) |  | $ | — |  | $ | (264)
​ The Group included the following items in costs of sales and services: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Years ended December 31: |  | 2024 |  | 2023 |  | 2022
Inventories as costs of goods sold (including depreciation expenses allocated to costs of goods sold) | ​ | $ | 73 | ​ | $ | 40 | ​ | $ | 80
​ The Group’s selling, general and administrative expenses comprised: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Years ended December 31: |  | 2024 |  | 2023 |  | 2022
Compensation (wages and salaries) | ​ | $ | 6,293 | ​ | $ | 5,418 | ​ | $ | 4,443
Legal and professional | ​ |  | 6,091 | ​ |  | 7,242 | ​ | ​ | 6,983
Accounting | ​ | ​ | 1,765 | ​ | ​ | 1,646 | ​ | ​ | 885
Consulting and fees | ​ | ​ | 3,693 | ​ | ​ | 3,095 | ​ | ​ | 6,529
Depreciation and amortization | ​ | ​ | 858 | ​ | ​ | 932 | ​ | ​ | 784
Office | ​ | ​ | 1,065 | ​ | ​ | 804 | ​ | ​ | 748
Reimbursement of expenses (net of recovery) | ​ | ​ | 679 | ​ | ​ | 886 | ​ | ​ | 5,607
Other | ​ | ​ | 4,891 | ​ | ​ | 4,159 | * | ​ | 2,501
​ | ​ | $ | 25,335 | ​ | $ | 24,182 | ​ | $ | 28,480
* Including expenses of $542 relating to a planned acquisition which was terminated in 2023. Additional information on the nature of costs and expenses ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Years Ended December 31: |  | 2024 |  | 2023 |  | 2022
Depreciation, depletion and amortization | ​ | $ | 7,221 | ​ | $ | 7,929 | ​ | $ | 10,699
Employee benefits expenses* | ​ |  | 8,044 | ​ |  | 8,057 | ​ |  | 7,194
Expenses for defined contribution plans and similar plans | ​ | ​ | — | ​ | ​ | 227 | ​ | ​ | 278
Termination benefits | ​ | ​ | 1,424 | ​ | ​ | — | ​ | ​ | 394
* Employee benefits expenses do not include the directors’ fees of the Company. For directors’ fees, see Note 24.

X
- Definition The entire disclosure for general information about financial statements. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 51 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_51&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Consolidated Statements of Operations + References No definition available. + Details
Name: | srl_DisclosureOfConsolidatedStatementsOfOperationsAbstract
Namespace Prefix: | srl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration